New cancer pill targets genetic weakness in advanced tumors
Disease control
Recruiting now
This is a first-in-human study to test a new oral drug called FORX-428 in adults with advanced solid tumors that have specific genetic mutations, like BRCA1/2. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll about 40 people wh…
Phase: PHASE1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC